Bank of America
RLMD icon

Bank of America’s Relmada Therapeutics RLMD Stock Holding History

Bank of America’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$877K Buy
125,941
+100,601
+397% +$476K ﹤0.01% 4580
2025
Q4 		$122K Buy
25,340
+25,077
+9,535% +$84K ﹤0.01% 5546
2025
Q3 		$528 Sell
263
-61
-19% -$59 ﹤0.01% 7579
2025
Q2 		$194 Sell
324
-13,392
-98% -$6.87K ﹤0.01% 7847
2025
Q1 		$3.7K Sell
13,716
-192,941
-93% -$64K ﹤0.01% 7262
2024
Q4 		$107K Sell
206,657
-1
-0% -$2 ﹤0.01% 6366
2024
Q3 		$670K Sell
206,658
-1,311
-0.6% -$4.25K ﹤0.01% 5306
2024
Q2 		$624K Sell
207,969
-2,607
-1% -$9.43K ﹤0.01% 5202
2024
Q1 		$979K Sell
210,576
-55
-0% -$265 ﹤0.01% 4948
2023
Q4 		$872K Sell
210,631
-2,904
-1% -$8.6K ﹤0.01% 5082
2023
Q3 		$641K Sell
213,535
-23,366
-10% -$69.4K ﹤0.01% 5144
2023
Q2 		$583K Buy
236,901
+199,567
+535% +$552K ﹤0.01% 5175
2023
Q1 		$84.4K Buy
37,334
+20,774
+125% +$71.6K ﹤0.01% 6313
2022
Q4 		$57.8K Buy
16,560
+2,695
+19% +$23.7K ﹤0.01% 6428
2022
Q3 		$513K Buy
13,865
+5,078
+58% +$141K ﹤0.01% 5377
2022
Q2 		$167K Buy
8,787
+2,051
+30% +$44.7K ﹤0.01% 6213
2022
Q1 		$182K Sell
6,736
-3,670
-35% -$75.9K ﹤0.01% 6525
2021
Q4 		$235K Sell
10,406
-1,875
-15% -$41.7K ﹤0.01% 6408
2021
Q3 		$322K Buy
12,281
+6,084
+98% +$163K ﹤0.01% 5961
2021
Q2 		$199K Sell
6,197
-1,581
-20% -$54.9K ﹤0.01% 6101
2021
Q1 		$274K Buy
7,778
+1,970
+34% +$68.9K ﹤0.01% 5808
2020
Q4 		$186K Sell
5,808
-1,751
-23% -$60.2K ﹤0.01% 5645
2020
Q3 		$284K Sell
7,559
-1,242
-14% -$48K ﹤0.01% 5080
2020
Q2 		$394K Sell
8,801
-5,161
-37% -$218K ﹤0.01% 4785
2020
Q1 		$476K Buy
+13,962
New +$563K ﹤0.01% 4533

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bank of America's RLMD Position: Q1 2026 in Review

Bank of America increased its Relmada Therapeutics (RLMD) stake by 397% in Q1 2026, buying an estimated $476K and bringing the position to 125,941 shares worth $877K. The position accounts for ﹤0.01% of the portfolio, ranked #4580.

Bank of America first reported a position in RLMD in Q1 2020 and has held it in 25 quarters since. The position peaked at $979K in Q1 2024. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Bank of America held 125,941 shares of Relmada Therapeutics worth $877K as of Q1 2026.
  • Bank of America bought 100,601 Relmada Therapeutics shares in Q1 2026, an estimated $476K.
  • Relmada Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4580 holding.
  • Bank of America first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Bank of America's Relmada Therapeutics position peaked at $979K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.